---
firstreceived_date: November 1, 2010
is_fda_regulated: 'Yes'
reference: []
overall_contact_backup: {}
completion_date:
  attributes:
    type: Actual
  value: May 2011
responsible_party: {}
firstreceived_results_date: 
is_section_801: 'Yes'
detailed_description: {}
link: []
has_expanded_access: 'No'
id: NCT01239758
intervention:
- intervention_name: ACE-031 (Extension of cohort 1 from core study, A031-03)
  other_name: []
  description: ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
  arm_group_label:
  - ACE-031 (Extension of cohort 1 from core study, A031-03)
  intervention_type: Biological
- intervention_name: ACE-031 (Extension of cohort 2 from core study, A031-03)
  other_name: []
  description: Up to 1.0 mg/kg subcutaneously once every 2 weeks for 24 weeks.
  arm_group_label:
  - ACE-031 (Extension of cohort 2 from core study, A031-03)
  intervention_type: Biological
- intervention_name: ACE-031 (Extension of cohort 3 from core study, A031-03)
  other_name: []
  description: Up to 2.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
  arm_group_label:
  - ACE-031 (Extension of cohort 3 from core study, A031-03)
  intervention_type: Biological
source: Acceleron Pharma, Inc.
eligibility:
  gender: Male
  maximum_age: N/A
  sampling_method: 
  minimum_age: 4 Years
  study_pop: {}
  criteria:
    textblock: |-
      Inclusion Criteria:

                -  Completion of participation in Study A031-03 and Investigator approval

                -  Continuation of corticosteroid therapy at the same absolute dose and schedule as on
                   Study A031-03

              Exclusion Criteria:

                -  Participation in any other therapeutic clinical trial

                -  Plans to have surgery during the course of the study
  healthy_volunteers: 'No'
removed_countries: {}
other_outcome: []
primary_completion_date:
  attributes:
    type: Actual
  value: May 2011
last_injected: '2015-09-26T05:39:07.713Z'
intervention_browse: {}
target_duration: 
number_of_arms: '3'
start_date: October 2010
why_stopped: This study was terminated based on preliminary safety data.
id_info:
  org_study_id: A031-06
  secondary_id: []
  nct_alias: []
  nct_id: NCT01239758
acronym: 
arm_group:
- description: 
  arm_group_label: ACE-031 (Extension of cohort 1 from core study, A031-03)
  arm_group_type: Experimental
- description: 
  arm_group_label: ACE-031 (Extension of cohort 2 from core study, A031-03)
  arm_group_type: Experimental
- description: 
  arm_group_label: ACE-031 (Extension of cohort 3 from core study, A031-03)
  arm_group_type: Experimental
sponsors:
  collaborator: []
  lead_sponsor:
    agency: Acceleron Pharma, Inc.
    agency_class: Industry
secondary_outcome:
- safety_issue: 'No'
  time_frame: Baseline to End-of-Study Visit, approximately 24 weeks later.
  description: 
  measure: Percent change in total lean body mass by DXA scan.
- safety_issue: 'No'
  time_frame: Baseline to End-of-Study Visit, approximately 24 weeks later.
  description: 
  measure: Percent change in total body and lumbar spine bone mineral density by DXA
    scan.
- safety_issue: 'No'
  time_frame: Baseline to End-of-Study Visit, approximately 24 weeks later.
  description: 
  measure: Percent change in muscle strength score by hand-held myometry.
- safety_issue: 'No'
  time_frame: Baseline to End-of-Study Visit, approximately 24 weeks later.
  description: 
  measure: Change in distance traveled in 6 minutes (standardized 6-Minute-Walk Test).
- safety_issue: 'No'
  time_frame: Baseline to End-of-Study Visit, approximately 24 weeks later.
  description: 
  measure: Change in time to travel 10 meters (standardized 10-Meter-Walk/Run test).
- safety_issue: 'No'
  time_frame: Baseline to End-of-Study Visit, approximately 24 weeks later.
  description: 
  measure: Change in pulmonary function tests.
study_type: Interventional
biospec_retention: 
overall_status: Terminated
primary_outcome:
- safety_issue: 'Yes'
  time_frame: From treatment initiation to End-of-Study Visit, approximately 24 weeks
    later.
  description: 
  measure: Number of patients with adverse events.
- safety_issue: 'Yes'
  time_frame: Baseline to End-of-Study Visit, approximately 24 weeks later.
  description: 
  measure: Change in laboratory parameters and vital signs.
overall_official: []
phase: Phase 2
location_countries:
  country:
  - Canada
condition:
- Duchenne Muscular Dystrophy
clinical_results: {}
study_design: 'Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy
  Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose:
  Treatment'
keyword: []
results_reference: []
oversight_info:
  has_dmc: 'Yes'
  authority:
  - 'Canada: Health Canada'
  - 'United States: Food and Drug Administration'
number_of_groups: 
location:
- status: 
  contact_backup: {}
  facility:
    name: Acceleron Investigative Site
    address:
      city: Calgary
      state: Alberta
      zip: 
      country: Canada
  investigator: []
  contact: {}
  geodata:
    latitude: 51.045
    formatted: Calgary, AB, Canada
    longitude: -114.057
    original: Calgary, Alberta
- status: 
  contact_backup: {}
  facility:
    name: Acceleron Investigative Site
    address:
      city: Hamilton
      state: Ontario
      zip: 
      country: Canada
  investigator: []
  contact: {}
  geodata:
    latitude: 43.244
    formatted: Hamilton, ON, Canada
    longitude: -79.889
    original: Hamilton, Ontario
- status: 
  contact_backup: {}
  facility:
    name: Acceleron Investigative Site
    address:
      city: London
      state: Ontario
      zip: 
      country: Canada
  investigator: []
  contact: {}
  geodata:
    latitude: 42.979
    formatted: London, ON, Canada
    longitude: -81.246
    original: London, Ontario
- status: 
  contact_backup: {}
  facility:
    name: Acceleron Investigative Site
    address:
      city: Ottawa
      state: Ontario
      zip: 
      country: Canada
  investigator: []
  contact: {}
  geodata:
    latitude: 45.422
    formatted: Ottawa, ON, Canada
    longitude: -75.697
    original: Ottawa, Ontario
official_title: An Open-Label Extension Study to Evaluate the Safety, Tolerability,
  and Pharmacodynamics of ACE-031 (ActRIIB-IgG1) in Subjects With Duchenne Muscular
  Dystrophy
verification_date: January 2013
required_header:
  url: https://clinicaltrials.gov/show/NCT01239758
  link_text: Link to the current ClinicalTrials.gov record.
overall_contact: {}
brief_title: Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy
biospec_descr: {}
condition_browse:
  mesh_term:
  - Muscular Dystrophies
  - Muscular Dystrophy, Duchenne
brief_summary:
  textblock: |-
    To evaluate the long-term safety and tolerability of ACE-031 administration in subjects with
          Duchenne muscular dystrophy (DMD) who participated in Study A031-03. [Note: This study was
          terminated based on preliminary safety data. Pending further analysis of safety data and
          discussion with health authorities, a new ACE-031 trial will be planned.]
enrollment:
  attributes:
    type: Actual
  value: '11'
lastchanged_date: January 30, 2013
